Synthon Hispania, S.L. (manufacturing of finished dosage form, primary and secondary packaging, physico-chemical batch control, batch release)

The drug is intended to reduce elevated platelet levels in patients at high risk of developing essential thrombocythemia if current treatment is ineffective or not tolerated by the patient.

Dosage form: capsules, hard

ATC: L01XX35